LINK Medical Research appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer
LINK Medical Research has been appointed by Ectin Research AB as CRO for its landmark Phase I/II Study of a new treatment for metastatic bladder cancer. This is significant news as bladder cancer is one of the most aggressive cancers; 50-70% of tumours recur and 10-20% become metastatic. Current treatments of metastatic bladder cancer require frequent, long hospital visits, have limited efficacy a